Information Provided By:
Fly News Breaks for December 9, 2019
Dec 9, 2019 | 07:01 EDT
BMO Capital analyst George Farmer raised his price target on Agios Pharmaceuticals to $49 and kept his Outperform rating after its mitapivat Phase 2 trial data in patients with non-transfusion-dependent thalassemia. The analyst notes that while not addressing the root cause of thalassemia, the trial findings may have "significant implications" for the ultimate mitapivat potential beyond pyruvate kinase deficiency. Farmer added that further upcoming data should demonstrate increased PK activity in unhealthy red blood cells purified from patients representing a wide disease spectrum.
News For AGIO From the Last 2 Days
There are no results for your query AGIO